Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: J Clin Gastroenterol. 2020 Sep;54(8):741–746. doi: 10.1097/MCG.0000000000001285

TABLE 1.

Characteristics of Cirrhotic Patients Receiving TEG

All Cirrhotics (n=106) CTP A (n=25) CTP B (n=25) CTP C (n=56)
Age [mean (SD)] 58.0 (10.8) 63.1 (10.9) 61.2 (8.2) 54.3 (10.6)
Gender, male (%) 62.3 80 51.5 51.8
Reason for getting TEG
 Bleeding 30 9 8 13
 Before liver transplant 42 9 11 22
 Before other procedure 19 3 4 13
 Evaluation of coagulopathy, bleeding risk stratification 15 5 2 8
Cause of liver diagnosis
 Alcoholic 32 11 6 25
 HCV 43 16 15 12
 NASH 16 2 3 11
 Autoimmune 3 0 0 3
 HBV 3 1 1 1
 PSC 5 1 1 3
 PBC 4 0 0 4
 Cryptogenic 4 0 3 1
 Other 2 1 0 2
Na-MELD [mean (SD)] 20.08 (10.7) 9.56 (3.9) 14.76 (4.8) 27.16 (9.4)
Platelets [mean (SD)] 108.33 (84.2) 155.72 (92.3) 113.68 (105.7) 84.79 (58.0)
INR [mean (SD)] 2.10 (2.1) 1.13 (0.2) 1.57 (0.4) 2.46 (1.3)
Patients receiving any blood product 24 hours after TEG
 Packed red blood cells 51 4 19 36
 Platelets 39 5 15 27
 FFP or cryoprecipitate 46 2 16 36
 Prothrombin complex concentrate 3 0 1 2
Needing to get another TEG over 24 h after for continued bleeding 18 1 4 13
Cancer diagnosis 41 11 17 13
Bleeding diathesis 2 1 0 1
DVT prophylaxis during TEG study 8 2 0 6
Therapeutic anticoagulation during TEG study 5 0 2 3

CTP indicates Child-Turcotte-Pugh; DVT, deep vein thrombosis; FFP, fresh frozen plasma; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; Na-MELD, sodium Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; TEG, thromboelastography